Single‐Dose Administration of MK‐0657, an NR2B‐Selective NMDA Antagonist, Does Not Result in Clinically Meaningful Improvement in Motor Function in Patients With Moderate Parkinson's Disease
Identifieur interne : 000959 ( Main/Exploration ); précédent : 000958; suivant : 000960Single‐Dose Administration of MK‐0657, an NR2B‐Selective NMDA Antagonist, Does Not Result in Clinically Meaningful Improvement in Motor Function in Patients With Moderate Parkinson's Disease
Auteurs : Addy [États-Unis] ; Assaid [États-Unis] ; Hreniuk [États-Unis] ; Stroh [États-Unis] ; Xu [États-Unis] ; Herring [États-Unis] ; Ellenbogen [États-Unis] ; Jinnah [États-Unis] ; Kirby [États-Unis] ; Leibowitz [États-Unis] ; Stewart [États-Unis] ; Tarsy [États-Unis] ; Tetrud [États-Unis] ; Stoch [États-Unis] ; Gottesdiener [États-Unis] ; Wagner [États-Unis]Source :
- The Journal of Clinical Pharmacology [ 0091-2700 ] ; 2009-07.
English descriptors
- KwdEn :
Abstract
The glutamatergic system is thought to contribute to the motor disturbances observed in Parkinson's disease. Blockade of glutamatergic activity by a selective antagonist of the NR2B subunit of the N‐methyl‐D‐aspartate (NMDA) receptor is associated with improvement in motor symptoms in a preclinical model of Parkinson's disease. A randomized, double‐blind, double‐dummy, placebo‐controlled, 3‐period crossover study was conducted in patients with moderate Parkinson's disease to evaluate the pharmacologic activity of MK‐0657, an NR2B‐selctive NMDA receptor antagonist. Patients (n = 16) received single oral doses of MK‐0657 7 mg, carbidopa/levodopa 25/250 mg (LD) as a positive control, and placebo, after which motor function was serially evaluated by means of the Unified Parkinson's Disease Rating Scale—Motor Examination (UPDRS‐ME). LD administration resulted in significant improvement in the UPDRS‐ME relative to placebo (P = .025), confirming the sensitivity of the test paradigm; however, the UPDRS‐ME change following MK‐0657 administration showed no improvement compared with placebo (P = .110) despite exceeding the target MK‐0657 plasma concentration of 400 nM. Although the administration of MK‐0657 was generally well tolerated, it was associated with increases in systolic and diastolic blood pressure relative to placebo. The results of this study do not support ongoing clinical development of MK‐0657 as a novel monotherapy for Parkinson's disease.
Url:
DOI: 10.1177/0091270009336735
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Single‐Dose Administration of MK‐0657, an NR2B‐Selective NMDA Antagonist, Does Not Result in Clinically Meaningful Improvement in Motor Function in Patients With Moderate Parkinson's Disease</title><author><name sortKey="Addy" sort="Addy" uniqKey="Addy" last="Addy">Addy</name></author><author><name sortKey="Assaid" sort="Assaid" uniqKey="Assaid" last="Assaid">Assaid</name></author><author><name sortKey="Hreniuk" sort="Hreniuk" uniqKey="Hreniuk" last="Hreniuk">Hreniuk</name></author><author><name sortKey="Stroh" sort="Stroh" uniqKey="Stroh" last="Stroh">Stroh</name></author><author><name sortKey="Xu" sort="Xu" uniqKey="Xu" last="Xu">Xu</name></author><author><name sortKey="Herring" sort="Herring" uniqKey="Herring" last="Herring">Herring</name></author><author><name sortKey="Ellenbogen" sort="Ellenbogen" uniqKey="Ellenbogen" last="Ellenbogen">Ellenbogen</name></author><author><name sortKey="Jinnah" sort="Jinnah" uniqKey="Jinnah" last="Jinnah">Jinnah</name></author><author><name sortKey="Kirby" sort="Kirby" uniqKey="Kirby" last="Kirby">Kirby</name></author><author><name sortKey="Leibowitz" sort="Leibowitz" uniqKey="Leibowitz" last="Leibowitz">Leibowitz</name></author><author><name sortKey="Stewart" sort="Stewart" uniqKey="Stewart" last="Stewart">Stewart</name></author><author><name sortKey="Tarsy" sort="Tarsy" uniqKey="Tarsy" last="Tarsy">Tarsy</name></author><author><name sortKey="Tetrud" sort="Tetrud" uniqKey="Tetrud" last="Tetrud">Tetrud</name></author><author><name sortKey="Stoch" sort="Stoch" uniqKey="Stoch" last="Stoch">Stoch</name></author><author><name sortKey="Gottesdiener" sort="Gottesdiener" uniqKey="Gottesdiener" last="Gottesdiener">Gottesdiener</name></author><author><name sortKey="Wagner" sort="Wagner" uniqKey="Wagner" last="Wagner">Wagner</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:FB23D0C2B58180650501C737A3F2A82C06411DC9</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1177/0091270009336735</idno><idno type="url">https://api.istex.fr/document/FB23D0C2B58180650501C737A3F2A82C06411DC9/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000998</idno><idno type="wicri:Area/Main/Curation">000870</idno><idno type="wicri:Area/Main/Exploration">000959</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Single‐Dose Administration of MK‐0657, an NR2B‐Selective NMDA Antagonist, Does Not Result in Clinically Meaningful Improvement in Motor Function in Patients With Moderate Parkinson's Disease</title><author><name sortKey="Addy" sort="Addy" uniqKey="Addy" last="Addy">Addy</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Merck & Co, Inc, Whitehouse Station</wicri:cityArea></affiliation></author><author><name sortKey="Assaid" sort="Assaid" uniqKey="Assaid" last="Assaid">Assaid</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Merck & Co, Inc, Whitehouse Station</wicri:cityArea></affiliation></author><author><name sortKey="Hreniuk" sort="Hreniuk" uniqKey="Hreniuk" last="Hreniuk">Hreniuk</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Merck & Co, Inc, Whitehouse Station</wicri:cityArea></affiliation></author><author><name sortKey="Stroh" sort="Stroh" uniqKey="Stroh" last="Stroh">Stroh</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Merck & Co, Inc, Whitehouse Station</wicri:cityArea></affiliation></author><author><name sortKey="Xu" sort="Xu" uniqKey="Xu" last="Xu">Xu</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Merck & Co, Inc, Whitehouse Station</wicri:cityArea></affiliation></author><author><name sortKey="Herring" sort="Herring" uniqKey="Herring" last="Herring">Herring</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Merck & Co, Inc, Whitehouse Station</wicri:cityArea></affiliation></author><author><name sortKey="Ellenbogen" sort="Ellenbogen" uniqKey="Ellenbogen" last="Ellenbogen">Ellenbogen</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Michigan</region></placeName><wicri:cityArea>Quest Research Institute, Bingham Farms</wicri:cityArea></affiliation></author><author><name sortKey="Jinnah" sort="Jinnah" uniqKey="Jinnah" last="Jinnah">Jinnah</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Department of Neurology, Johns Hopkins Hospital, Baltimore</wicri:cityArea></affiliation></author><author><name sortKey="Kirby" sort="Kirby" uniqKey="Kirby" last="Kirby">Kirby</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Arizona</region></placeName><wicri:cityArea>Pivotal Research Center, Peoria</wicri:cityArea></affiliation></author><author><name sortKey="Leibowitz" sort="Leibowitz" uniqKey="Leibowitz" last="Leibowitz">Leibowitz</name><affiliation wicri:level="2"><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>California Clinical Trials, Glendale</wicri:cityArea></affiliation></author><author><name sortKey="Stewart" sort="Stewart" uniqKey="Stewart" last="Stewart">Stewart</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>Radiant Research, Dallas</wicri:cityArea></affiliation></author><author><name sortKey="Tarsy" sort="Tarsy" uniqKey="Tarsy" last="Tarsy">Tarsy</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Beth Israel Deaconess Medical Center, Boston</wicri:cityArea></affiliation></author><author><name sortKey="Tetrud" sort="Tetrud" uniqKey="Tetrud" last="Tetrud">Tetrud</name><affiliation wicri:level="2"><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>The Parkinson's Institute, Sunnyvale</wicri:cityArea></affiliation></author><author><name sortKey="Stoch" sort="Stoch" uniqKey="Stoch" last="Stoch">Stoch</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Merck & Co, Inc, Whitehouse Station</wicri:cityArea></affiliation></author><author><name sortKey="Gottesdiener" sort="Gottesdiener" uniqKey="Gottesdiener" last="Gottesdiener">Gottesdiener</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Merck & Co, Inc, Whitehouse Station</wicri:cityArea></affiliation></author><author><name sortKey="Wagner" sort="Wagner" uniqKey="Wagner" last="Wagner">Wagner</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Merck & Co, Inc, Whitehouse Station</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j">The Journal of Clinical Pharmacology</title><idno type="ISSN">0091-2700</idno><idno type="eISSN">1552-4604</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2009-07">2009-07</date><biblScope unit="volume">49</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="856">856</biblScope><biblScope unit="page" to="864">864</biblScope></imprint><idno type="ISSN">0091-2700</idno></series><idno type="istex">FB23D0C2B58180650501C737A3F2A82C06411DC9</idno><idno type="DOI">10.1177/0091270009336735</idno><idno type="ArticleID">JCPH5323</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0091-2700</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>NMDA</term><term>NR2B</term><term>Parkinson's disease</term><term>glutamate receptor</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The glutamatergic system is thought to contribute to the motor disturbances observed in Parkinson's disease. Blockade of glutamatergic activity by a selective antagonist of the NR2B subunit of the N‐methyl‐D‐aspartate (NMDA) receptor is associated with improvement in motor symptoms in a preclinical model of Parkinson's disease. A randomized, double‐blind, double‐dummy, placebo‐controlled, 3‐period crossover study was conducted in patients with moderate Parkinson's disease to evaluate the pharmacologic activity of MK‐0657, an NR2B‐selctive NMDA receptor antagonist. Patients (n = 16) received single oral doses of MK‐0657 7 mg, carbidopa/levodopa 25/250 mg (LD) as a positive control, and placebo, after which motor function was serially evaluated by means of the Unified Parkinson's Disease Rating Scale—Motor Examination (UPDRS‐ME). LD administration resulted in significant improvement in the UPDRS‐ME relative to placebo (P = .025), confirming the sensitivity of the test paradigm; however, the UPDRS‐ME change following MK‐0657 administration showed no improvement compared with placebo (P = .110) despite exceeding the target MK‐0657 plasma concentration of 400 nM. Although the administration of MK‐0657 was generally well tolerated, it was associated with increases in systolic and diastolic blood pressure relative to placebo. The results of this study do not support ongoing clinical development of MK‐0657 as a novel monotherapy for Parkinson's disease.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Arizona</li><li>Californie</li><li>Maryland</li><li>Massachusetts</li><li>Michigan</li><li>New Jersey</li><li>Texas</li></region></list><tree><country name="États-Unis"><region name="New Jersey"><name sortKey="Addy" sort="Addy" uniqKey="Addy" last="Addy">Addy</name></region><name sortKey="Assaid" sort="Assaid" uniqKey="Assaid" last="Assaid">Assaid</name><name sortKey="Ellenbogen" sort="Ellenbogen" uniqKey="Ellenbogen" last="Ellenbogen">Ellenbogen</name><name sortKey="Gottesdiener" sort="Gottesdiener" uniqKey="Gottesdiener" last="Gottesdiener">Gottesdiener</name><name sortKey="Herring" sort="Herring" uniqKey="Herring" last="Herring">Herring</name><name sortKey="Hreniuk" sort="Hreniuk" uniqKey="Hreniuk" last="Hreniuk">Hreniuk</name><name sortKey="Jinnah" sort="Jinnah" uniqKey="Jinnah" last="Jinnah">Jinnah</name><name sortKey="Kirby" sort="Kirby" uniqKey="Kirby" last="Kirby">Kirby</name><name sortKey="Leibowitz" sort="Leibowitz" uniqKey="Leibowitz" last="Leibowitz">Leibowitz</name><name sortKey="Stewart" sort="Stewart" uniqKey="Stewart" last="Stewart">Stewart</name><name sortKey="Stoch" sort="Stoch" uniqKey="Stoch" last="Stoch">Stoch</name><name sortKey="Stroh" sort="Stroh" uniqKey="Stroh" last="Stroh">Stroh</name><name sortKey="Tarsy" sort="Tarsy" uniqKey="Tarsy" last="Tarsy">Tarsy</name><name sortKey="Tetrud" sort="Tetrud" uniqKey="Tetrud" last="Tetrud">Tetrud</name><name sortKey="Wagner" sort="Wagner" uniqKey="Wagner" last="Wagner">Wagner</name><name sortKey="Xu" sort="Xu" uniqKey="Xu" last="Xu">Xu</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000959 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000959 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:FB23D0C2B58180650501C737A3F2A82C06411DC9
|texte= Single‐Dose Administration of MK‐0657, an NR2B‐Selective NMDA Antagonist, Does Not Result in Clinically Meaningful Improvement in Motor Function in Patients With Moderate Parkinson's Disease
}}
| This area was generated with Dilib version V0.6.23. |  |